••
A critical shortage of Lenacapavir, a groundbreaking twice-yearly injectable drug for HIV prevention, has hit several Nigerian states shortly after the commencement of a federal pilot program. The stock-out has sparked a scramble among key populations, particularly sex workers and other high-risk individuals who rely on the medication to mitigate the risk of infection. This sudden depletion of supplies highlights the high demand for long-acting antiretroviral options in Nigeria's ongoing battle against HIV/AIDS, signaling a shift in how vulnerable populations prefer to manage their health.
The shortage has been reported most acutely in Benue, Kwara, Gombe, and Cross River states. These regions, which were part of the initial phase of the Federal Government's rollout, saw their inventories exhausted almost immediately after distribution began. Health workers and advocacy groups have noted that the convenience of a biannual injection, as opposed to the daily regimen required by traditional oral Pre-Exposure Prophylaxis (PrEP), has driven an unprecedented level of interest and uptake among eligible Nigerians.
Lenacapavir’s introduction was seen as a major milestone in Nigeria’s public health policy, offering a more discreet and manageable alternative for those at high risk of exposure. However, the rapid exhaustion of stock suggests that initial procurement volumes may have underestimated the public’s readiness to adopt the new technology. For sex workers in particular, the injectable form provides a level of privacy and consistency that is often difficult to maintain with daily pills, making the current lack of availability a significant setback for localized prevention efforts during this pilot phase.
As the Federal Government and health agencies assess the situation, the focus shifts to scaling up procurement and improving the supply chain to prevent future disruptions. Ensuring a steady supply of Lenacapavir is essential not only for the success of the pilot program but also for sustaining the gains made in reducing HIV transmission rates across the country. The current scramble serves as a clear indicator of the public's appetite for innovative health solutions, placing the onus on authorities to bridge the gap between demand and delivery to protect those most at risk.